QLT sells acne treatment product to Allergan (The Globe and Mail)
Deal for $150-million is expected to close in the third quarter
Breakthrough Isolaz(TM) Acne Therapy Featured in U.S. News & World Report: (PR Newswire via Yahoo! Finance)
Aesthera Corporation's Isolaz painless acne therapy has been featured in the June 9, 2008, issue of U.S. News & World Report, a leading national weekly news magazine. The publication describes Isolaz acne therapy as "an advance against acne" and reports that the Isolaz is the first treatment device FDA cleared to treat comedonal and pustular acne, in addition to mild to moderate, inflammatory ...
Cipher receives patent notice of allowance for Cip-Isotretinoin (Pharmaceutical Business Review)
Cipher Pharmaceuticals has announced that the US Patent and Trademark Office has issued a patent notice of allowance for Cip-Isotretinoin, the companys novel formulation of the acne medication isotretinoin.
QLT sells sell acne medicine Aczone to Allergan for US$150 million (The Canadian Press via Yahoo! Canada News)
VANCOUVER - QLT Inc. (TSX:QLT) has sold its worldwide rights to Aczone, a prescription medicine for acne, to Allergan Inc. (NYSE:AGN) for US$150 million.
Allergan Buys Acne Drug From QLT for $150 Million (Update2) (Bloomberg.com)
June 9 (Bloomberg) -- Allergan Inc., the maker of the wrinkle remover Botox, will pursue a younger crowd, spending $150 million to acquire a new acne drug from Canada's QLT Inc.
|
